GT
CRNX

Glenmede Trust’s Crinetics Pharmaceuticals CRNX Stock Holding History

Glenmede Trust’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
31,933
+2,688
+9% +$99.9K 0.01% 722
2026
Q1 		$1.06M Buy
29,245
+12,301
+73% +$549K 0.01% 722
2025
Q4 		$789K Buy
+16,944
New +$754K ﹤0.01% 793
2025
Q1 		$582K Sell
17,352
-38
-0.2% -$1.42K ﹤0.01% 858
2024
Q4 		$889K Buy
17,390
+246
+1% +$13.8K ﹤0.01% 758
2024
Q3 		$876K Sell
17,144
-807
-4% -$41.6K ﹤0.01% 756
2024
Q2 		$804K Buy
17,951
+11,013
+159% +$509K ﹤0.01% 751
2024
Q1 		$325K Buy
+6,938
New +$271K ﹤0.01% 1035
2023
Q4 		– Sell
-7,518
Closed -$224K – 1305
2023
Q3 		$224K Buy
+7,518
New +$155K ﹤0.01% 1073

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Glenmede Trust's CRNX Position: Q2 2026 in Review

Glenmede Trust increased its Crinetics Pharmaceuticals (CRNX) stake by 9.2% in Q2 2026, buying an estimated $99.9K and bringing the position to 31,933 shares worth $1.19M. The position accounts for 0.01% of the portfolio, ranked #722.

Glenmede Trust first reported a position in CRNX in Q3 2023 and has held it in 9 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Glenmede Trust held 31,933 shares of Crinetics Pharmaceuticals worth $1.19M as of Q2 2026.
  • Glenmede Trust bought 2,688 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $99.9K.
  • Crinetics Pharmaceuticals made up 0.01% of Glenmede Trust's portfolio in Q2 2026, its #722 holding.
  • Glenmede Trust first reported a position in Crinetics Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.